1. Home
  2. AMCI vs CRBP Comparison

AMCI vs CRBP Comparison

Compare AMCI & CRBP Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

AMCI

AMC Robotics Corporation Common Stock

N/A

Current Price

$7.14

Market Cap

150.0M

Sector

Finance

ML Signal

N/A

Logo Corbus Pharmaceuticals Holdings Inc.

CRBP

Corbus Pharmaceuticals Holdings Inc.

N/A

Current Price

$9.97

Market Cap

134.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
AMCI
CRBP
Founded
2021
2009
Country
United States
United States
Employees
N/A
N/A
Industry
Blank Checks
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
150.0M
134.8M
IPO Year
N/A
2014

Fundamental Metrics

Financial Performance
Metric
AMCI
CRBP
Price
$7.14
$9.97
Analyst Decision
Strong Buy
Analyst Count
0
7
Target Price
N/A
$46.17
AVG Volume (30 Days)
50.6K
152.1K
Earning Date
01-01-0001
06-15-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$4,822,272.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$100.00
P/E Ratio
$33.37
N/A
Revenue Growth
N/A
97.62
52 Week Low
$3.60
$4.64
52 Week High
$15.75
$20.56

Technical Indicators

Market Signals
Indicator
AMCI
CRBP
Relative Strength Index (RSI) 56.48 70.35
Support Level $5.84 $9.86
Resistance Level $7.75 $11.64
Average True Range (ATR) 0.66 0.58
MACD 0.06 0.24
Stochastic Oscillator 74.62 96.56

Price Performance

Historical Comparison
AMCI
CRBP

About AMCI AMC Robotics Corporation Common Stock

AMC Robotics Corp is an artificial intelligence services company that develops robotic solutions designed to support operational efficiency across sectors such as logistics and manufacturing. The company develops robotics and automation technologies designed to improve logistics operations. Its robots use sensors and visual AI to support real-time decision-making, contributing to safer and more efficient warehouse operations. It builds autonomous robots for use in logistics and warehousing.

About CRBP Corbus Pharmaceuticals Holdings Inc.

Corbus Pharmaceuticals Holdings Inc is a precision oncology company with a diversified portfolio and is committed to helping people defeat serious illness by bringing scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.

Share on Social Networks: